Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine Inc (NASDAQ: EDIT), a leader in CRISPR-based genome editing, provides this centralized hub for tracking all corporate developments and scientific advancements. Access real-time updates on clinical trial progress, regulatory milestones, and financial disclosures essential for monitoring this pioneering biotech firm.
This resource aggregates EDIT's press releases, partnership announcements, and peer-reviewed research findings. Investors will find critical updates on pipeline therapies for genetic disorders, while analysts gain insights into strategic initiatives shaping the genomic medicine landscape. Content spans quarterly earnings, intellectual property developments, and preclinical breakthroughs.
Key categories include therapy authorization updates, collaboration agreements with research institutions, and presentations at major medical conferences. All materials are sourced directly from Editas Medicine and verified financial filings to ensure reliability.
Bookmark this page for efficient tracking of EDIT's progress in developing CRISPR/Cas9 and Cas12a therapies. Check regularly for authoritative updates on one of biotech's most innovative gene-editing platforms.
Editas Medicine (Nasdaq: EDIT) announced a leadership transition as Chief Financial Officer Erick J. Lucera will step down effective March 28, 2025, to pursue an external opportunity. Amy Parison, current Senior Vice President of Finance, has been appointed as the new CFO.
Parison brings over 18 years of financial, accounting, and business development experience in life sciences to the role. During her two-and-a-half-year tenure at Editas, she has been instrumental in equity financings, licensing transactions, and royalty monetization. Her previous experience includes positions at Rubius Therapeutics as Corporate Controller and various roles at Vertex Pharmaceuticals.
CEO Gilmore O'Neill praised Parison's financial decision-making, accounting acumen, and team leadership abilities, while acknowledging Lucera's contributions in positioning Editas financially and developing talent.
Editas Medicine (NASDAQ: EDIT) reported its Q4 and full year 2024 financial results, highlighting progress in its in vivo gene editing programs. The company remains on track to declare two development candidates in mid-2025: one for hematopoietic stem cells (HSCs) and another for liver cells.
Financial highlights include:
- Q4 2024 net loss of $45.4 million ($0.55 per share)
- Full year 2024 net loss of $237.1 million ($2.88 per share)
- Cash position of $269.9 million as of December 31, 2024
- Operational runway extended into Q2 2027
The company discontinued development of reni-cel program in December 2024, resulting in a 65% workforce reduction. Restructuring charges of $12.2 million were recorded in Q4 2024. The company's strategic focus has shifted to becoming a leader in in vivo gene editing, with promising preclinical data showing potential for gene upregulation across multiple tissues.
Editas Medicine (NASDAQ: EDIT) has announced it will release its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, through a press release and SEC filings. The company has decided to discontinue hosting quarterly financial results conference calls.
The company's management team will participate in three major healthcare investor conferences in March: the TD Cowen 45th Annual Health Care Conference in Boston on March 3, the Leerink Partners Global Healthcare Conference in Miami on March 10, and the Barclays 27th Annual Global Healthcare Conference in Miami on March 11. All presentations will be in a fireside chat format and will be accessible via webcast on the company's website for approximately 30 days after each event.
Editas Medicine (EDIT) has announced significant progress in its gene editing programs, highlighting new preclinical proof of concept data and strategic priorities through 2027. The company achieved in vivo preclinical proof of concept for editing hematopoietic stem cells (HSCs) in non-human primates and demonstrated successful liver cell editing, marking important steps toward treating sickle cell disease and beta thalassemia.
Key 2025 milestones include declaring two in vivo development candidates and presenting additional preclinical data. The company's 2025-2027 strategic priorities include submitting at least one IND/CTA, achieving human in vivo proof of concept, and initiating late-stage trials.
Financially, Editas reports approximately $270 million in cash and equivalents as of December 31, 2024, with an operational runway extending into Q2 2027.
Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Gilmore O'Neill, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
Interested parties can access a live webcast of the presentation through the "Investors" section of the Editas Medicine website. The presentation recording will remain available on the company's website for approximately 30 days after the event.
Editas Medicine (EDIT) announced a strategic transition to focus exclusively on in vivo CRISPR-edited medicines, following recent breakthroughs in preclinical studies. The company achieved ~40% editing of the HBG1/2 promoter site using their proprietary targeted lipid nanoparticle delivery system, resulting in 20% HbF expressing human red blood cells. They also demonstrated high-efficiency liver editing in non-human primates.
As part of this transition, Editas is ending development of reni-cel and implementing significant cost-saving measures, including a 65% workforce reduction over the next six months. Several management changes were announced, including the departure of Chief Medical Officer Baisong Mei and two board members. The restructuring is expected to extend the company's cash runway into Q2 2027.
Editas Medicine (NASDAQ: EDIT) presented updated clinical data from the Phase 1/2/3 RUBY trial of reni-cel in 28 patients with severe sickle cell disease (SCD). The trial demonstrated positive results with 27 of 28 patients remaining free of vaso-occlusive events post-treatment. Key findings include early normalization of total hemoglobin from 9.8 g/dL at baseline to 13.8 g/dL at Month 6, and sustained fetal hemoglobin levels above 40%.
The treatment was well-tolerated with a safety profile consistent with myeloablative busulfan conditioning. Patients showed successful engraftment with median times of 23 days for neutrophil and 25 days for platelet engraftment. Only two serious adverse events possibly related to reni-cel were reported. The median follow-up was 9.5 months, with 11 patients having more than one year of follow-up.
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced its participation in three major healthcare investor conferences. The company will be featured in fireside chat sessions at Guggenheim's Inaugural Healthcare Innovation Conference on November 12 at 4:00 p.m. ET in Boston, the Stifel 2024 Healthcare Conference on November 19 at 1:50 p.m. ET in New York, and the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 1:20 p.m. ET in Coral Gables. Live webcasts will be available on the company's website, with replays accessible for approximately 30 days after each event.
Editas Medicine (EDIT) reported Q3 2024 financial results, highlighting a net loss of $62.1 million ($0.75 per share). The company achieved preclinical proof of concept for in vivo HBG1/2 editing in HSPCs using proprietary targeted LNP technology for sickle cell disease and beta thalassemia treatment. Cash position stands at $265.1 million, expected to fund operations into Q2 2026. The company secured a $57 million upfront payment from DRI Healthcare Trust through the sale of certain future license fees. Research and development expenses increased to $47.6 million, while revenues decreased to $0.1 million.
Editas Medicine (Nasdaq: EDIT) announced significant progress towards its 2024 goals, including achieving in vivo preclinical proof of concept for hematopoietic stem and progenitor cell (HSPC) editing. The company utilized its proprietary targeted lipid nanoparticle (tLNP) to achieve a 29% editing level in HSPCs after a single dose, resulting in 20% HbF-expressing human red blood cells. This advancement is important for developing an in vivo treatment for sickle cell disease and beta thalassemia.
Editas also initiated a process to partner or out-license reni-cel, focusing resources on in vivo pipeline development. The company completed enrollment for the RUBY trial for severe sickle cell disease and the EdiTHAL trial for transfusion-dependent beta thalassemia. Additionally, Editas secured $57 million in non-dilutive capital through a sale agreement with DRI Healthcare Trust and ended Q3 2024 with approximately $265 million in cash and equivalents.